Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.56 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20325045 | 0.88 | BCHE (0.61) | PRMT5WDR77BCHEMAOBMAOA | |
| SCHEMBL31507093 | 0.88 | PRMT5 (0.70) | PRMT5WDR77NPC1RAB9AMEN1 | |
| SCHEMBL20324489 | 0.87 | PRMT5 (0.50) | PRMT5WDR77LMNANPC1RAB9A | |
| SCHEMBL20314086 | 0.87 | PRMT5 (0.57) | PRMT5WDR77BCHEMEN1KMT2A | |
| SCHEMBL20324378 | 0.87 | LMNA (0.55) | LMNANPC1RAB9ABCHEMAOB | |
| SCHEMBL20325092 | 0.86 | PRMT5 (0.74) | PRMT5WDR77MAOBMAOACXCR4 | |
| SCHEMBL20324384 | 0.84 | EP300 (0.51) | PRMT5WDR77NPC1RAB9ABCHE | |
| SCHEMBL20324371 | 0.83 | CYP3A4 (0.57) | PRMT5WDR77LMNAMEN1KMT2A | |
| SCHEMBL20324385 | 0.83 | BCHE (0.47) | PRMT5WDR77BCHEMEN1KMT2A | |
| SCHEMBL20324949 | 0.81 | GAA (0.54) | PRMT5WDR77LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115339-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2020-04-16 | — | — | US | disclosed |
| US-10464896-B2 | Efflux-pump inhibitors and therapeutic uses thereof | Basilea Pharmaceutica International AG (CH) | 2019-11-05 | — | — | US | disclosed |
| US-20180179158-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115339-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCC1, ABCC3 | PRMT5 3801/4885WDR77 1607/4885LMNA 2385/4885 |
| US-10464896-B2 | Efflux-pump inhibitors and therapeutic uses thereof | ABCB11, ABCC1, ABCC3 | PRMT5 3780/4885WDR77 1540/4885LMNA 2482/4885 |
| US-20180179158-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCC1, ABCC3 | PRMT5 3780/4885WDR77 1540/4885LMNA 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.